BCR-ABL mutant kinetics in CML patients treated with dasatinib

Leukemia Research

Volumn 31, Issue 6, 2007, Pages 865-868

  Nicolini, Franck E ^a   Chabane, Kaddour ^b   Tigaud, Isabelle ^b   Michallet, Mauricette ^a   Magaud, Jean Pierre ^b   Hayette, Sandrine ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

BCR ABL mutations; CML imatinib resistant patients; Dasatinib

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOGENETICS; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AGED; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 34249799017     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.12.003     Document Type: Article

References (8)

1. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in Imatinib-resistant Philadelphia chromosome positive leukemias. N Engl J Med 354 (2006) 2531-2541
2. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
3. O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
4. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia-a Europe against cancer program. Leukemia 17 (2003) 2318-2357
5. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors-review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108 (2006) 28-37
6. Hayette S., Michallet M., Baille M.-L., Magaud J.-P., and Nicolini F.E. The assessment and the follow-up of the proportion of T315I Mutant Bcr-Abl transcripts can guide adequate therapeutic strategy in CML patient. Leuk Res 29 (2005) 1073-1077
7. Khorashad J.S., Anand M., Marin D., Saunders S., Al-Jabary T., Iqbal A., et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 20 (2006) 658-663
8. Burgess M.R., Skaggs B.J., Shah N.P., Lee F.Y., and Sawyers C.L. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 102 (2005) 3395-4000